Persones / Equip Humà

Marçal Pastor-Anglada

Buscador de publicacions

Publicacions

  • Errasti-Murugarren E, ESTHER PATRICIA DIAZ GONZALEZ, Godoy V, Riquelme G and Pastor-Anglada M.

    Expression and distribution of nucleoside transporter proteins in the human syncytiotrophoblast.

    MOLECULAR PHARMACOLOGY . 80(5): 809-817. Nº de cites: 23

    [doi:10.1124/mol.111.071837]

  • Domingo P, Torres-Torronteras J, Pomar V, Giralt M, Domingo JC, Gutierrez Mdel M, Gallego-Escuredo JM, Mateo MG, Cano-Soldado P, Fernandez I, Pastor-Anglada M, Vidal F, Villarroya-Gombau F, Andreu A and Marti R.

    Uridine metabolism in HIV-1-infected patients: effect of infection, of antiretroviral therapy and of HIV-1/ART-associated lipodystrophy syndrome.

    PLoS One . 5(11): . Nº de cites: 10

    [doi:10.1371/journal.pone.0013896]

  • Errasti-Murugarren E, Casado FJ and Pastor-Anglada M.

    Different N-terminal motifs determine plasma membrane targeting of the human concentrative nucleoside transporter 3 in polarized and nonpolarized cells.

    MOLECULAR PHARMACOLOGY . 78(5): 795-803. Nº de cites: 13

    [doi:10.1124/mol.110.065920]

  • Huber-Ruano I, Pinilla-Macua I, Torres G, Casado FJ and Pastor-Anglada M.

    Link between high-affinity adenosine concentrative nucleoside transporter-2 (CNT2) and energy metabolism in intestinal and liver parenchymal cells.

    J CELL PHYSIOL . 225(2): 620-630. Nº de cites: 16

    [doi:10.1002/jcp.22254]

  • Errasti-Murugarren E, Molina-Arcas M, Casado FJ and Pastor-Anglada M.

    The human concentrative nucleoside transporter-3 C602R variant shows impaired sorting to lipid rafts and altered specificity for nucleoside-derived drugs.

    MOLECULAR PHARMACOLOGY . 78(2): 157-165. Nº de cites: 16

    [doi:10.1124/mol.110.063552]

  • Gorraitz E, Pastor-Anglada M and Lostao MP.

    Effects of Na+ and H+ on steady-state and presteady-state currents of the human concentrative nucleoside transporter 3 (hCNT3).

    PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY . 460(3): 617-632. Nº de cites: 5

    [doi:10.1007/s00424-010-0846-9]

  • Errasti-Murugarren E and Pastor-Anglada M.

    Drug transporter pharmacogenetics in nucleoside-based therapies.

    Pharmacogenomics . 11(6): 809-841. Nº de cites: 43

    [doi:10.2217/pgs.10.70]

  • Molina-Arcas M and Pastor-Anglada M.

    Role of nucleoside transporters in nucleoside-derived drug sensitivity.

    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS . 29(4-6): 335-346. Nº de cites: 9

    [doi:10.1080/15257771003729823]

  • Fernández-Calotti P and Pastor-Anglada M.

    All-trans-retinoic acid promotes trafficking of human concentrative nucleoside transporter-3 (hCNT3) to the plasma membrane by a TGF-beta1-mediated mechanism.

    JOURNAL OF BIOLOGICAL CHEMISTRY . 285(18): 13589-13598. Nº de cites: 19

    [doi:10.1074/jbc.M109.055673]

  • Farías M, Puebla C, Westermeier F, Jo MJ, Pastor-Anglada M, Casanello P and Sobrevia L.

    Nitric oxide reduces SLC29A1 promoter activity and adenosine transport involving transcription factor complex hCHOP-C/EBPalpha in human umbilical vein endothelial cells from gestational diabetes.

    CARDIOVASC RES . 86(1): 45-54. Nº de cites: 39

    [doi:10.1093/cvr/cvp410]